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DEAR EDITOR, The first UK national COVID-19 lockdown began
on 23 March 2020. Immediately, almost all outpatient health-
care service requests temporarily focused exclusively on urgent
referrals and 2-week-wait urgent cancer referrals, with restric-
tions due to staff sickness, redeployment and changing work
environments. Additionally, patient anxiety regarding attend-
ing appointments and perceived overburdening of healthcare
resources resulted in fewer presentations.1
Technological advancements have arisen from challenging
circumstances. The National Cancer Registration and Analysis
Service (NCRAS), England, has developed a Rapid Cancer
Registration Dataset (RCRD). Due to automated data feeds, lag
time from diagnosis to registration has been reduced from 18
to 4 months; however, data have not been quality assured to
the same standards and completeness.2,3 We identify how the
pandemic has affected skin cancer.
The RCRD2,3 provides estimates of cancer incidence using
data from January 2018 to November 2020. The main
resource is multidisciplinary team meeting datasets, which are
not a reliable source for basal cell carcinomas (BCCs) and
cutaneous squamous cell carcinomas (cSCCs), effectively
excluding them. RCRD tumour resection procedures are iden-
tified as a definitive treatment, for example an excision but
not a diagnostic biopsy.
A separate tool to identify BCC and cSCC pathology reports
received by NCRAS before registration was developed for
quality assurance; it was not developed to report incidence
and so should be interpreted cautiously.4 Pathology reports
duplicate tumours when there are diagnostic biopsies, re-exci-
sions, recurrences and supplementary reports. Furthermore,
these data have not been quality assessed and therefore they
are best interpreted as a representation of workload rather
than incidence. The date of the report used is the date of sam-
ple collection preferentially.
Both methods are crude and not the gold standard of
tumour registration. Therefore they are not representative of
the true incidence but are rather an early, rapid estimate. All
reported proportions represent a comparison of the same
month or period of the previous year.
In May 2020, melanoma diagnoses reduced to 54%, increas-
ing to 83% by November 2020. During the 8-month period
from April 2020 to November 2020, melanoma diagnoses
reduced to 72%, with 2671 fewer melanomas diagnosed. Like-
wise, a reduction was seen in the diagnosis of all malignant
cancers (excluding nonmelanoma skin cancer, NMSC) (74%),
prostate cancer (64%), breast cancer (73%) and lung cancer
(88%) over the same period (Figure 1a). The proportion of
resection procedures in May 2020 fell to 69%, with an increase
to 87% by November 2020 (Figure 1b). Cancer Waiting Times
first treatments for melanoma similarly fell to 58% in May
2020 and rose to 91% by December 2020 (Figure 1c). Pathol-
ogy reports for cSCCs and BCCs in April 2020 fell to 58% and
22%, respectively. By September 2020 counts increased to 95%
for cSCCs and 72% for BCCs (Figure 1d).
Undoubtedly, fewer cancer diagnoses are being made dur-
ing the pandemic and an incomplete rebound is seen. Mela-
noma incidence decreased more than the incidence of all
cancers overall (excluding NMSC); however, it is comparable
with that of other cancers. BCCs are typically downgraded to
routine pathways once diagnosed unless considered high risk,
and therefore BCC pathology report counts drop substantially
more than for cSCC.
Comparatively, as a proportion of activity for the same
month of the previous year, in Australia, a reduction in surgi-
cal procedures to 82% for cSCC and BCC, and 75% for mela-
noma was seen at the pandemic onset, with a more rapid
recovery.5 In Ontario, Canada, cSCC and BCC biopsies reduced
to 82% and melanoma biopsies to 73% at the onset of the
pandemic, with improvements seen in the following
10 weeks.6 In a study of 143 US practices, melanoma diag-
noses fell to 304%, SCCs to 223% and BCCs to 141% in
April 2020, but have since improved.7 Overall, a less substan-
tial reduction in services is seen in countries where COVID-19
counts remained lower.
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The main limitation of these data is the lack of standard
quality assurance as a result of attaining more rapid access to
data. NCRAS report that the RCRD melanoma data reported in
Figure 1(a) record 13% false negative (missing) and 9% false
positive (additional) compared with formally registered cases
in 20182,3 Although crude, these data are essential to under-
standing the wider repercussions of the COVID-19 pandemic
beyond those directly infected. Early concerns precipitated the
‘help us, help you’ National Health Service campaign in Octo-
ber 2020,8 which promoted support for public access to
healthcare services during the pandemic.
It is essential to ensure that skin cancer services continue,
with virtual appointments playing an increasingly important
role. It is of grave concern that the decline in cancer incidence
represents patients who are likely to present later, resulting in
worse morbidity and mortality outcomes. Further research
must be undertaken to understand better the long-term health-
care consequences of the pandemic to ensure we are able to
prepare for further COVID-19 waves and future national emer-
gencies.
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Figure 1 (a) Cancer diagnoses by cancer group and month, Rapid Cancer Registration Dataset (RCRD), England; working-day-adjusted. (b)
Proportion of tumour resection procedures, by cancer group and month, RCRD, England. (c) First treatments by cancer group and month, Cancer
Waiting Times data, England; working-day-adjusted. (d) Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) pathology
reports received at the National Cancer Registration and Analysis Service, CancerStats2 keratinocyte cancer report, England. All data are
comparisons with the same month in the previous year. NMSC, non-melanoma skin cancer.
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Cutaneous squamous cell carcinoma is
associated with Lynch syndrome: widening the
spectrum of Lynch syndrome-associated
tumours
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DEAR EDITOR, Lynch syndrome (LS) is caused by a germline
mutation in one of the mismatch repair (MMR) genes. Indi-
viduals with LS have an increased risk of developing colorectal
and many other tumours including skin tumours.1 Sebaceous
neoplasms and keratoacanthomas are skin tumours associated
with LS, also known as Muir–Torre syndrome.2 For cutaneous
squamous cell carcinoma (SCC), an association with LS has
been suggested.3–5 Recently, a 12-fold increased risk for seba-
ceous carcinoma and SCC has been described in individuals
with LS compared with the Dutch general population at the
age of 60 years.6
Our aim was to evaluate whether cutaneous SCC is part of
the LS tumour spectrum by evaluating the MMR status of cuta-
neous SCCs diagnosed in a cohort of individuals with LS. Fur-
thermore, we evaluated the concordance between MMR
immunohistochemistry (IHC) and microsatellite instability
(MSI) polymerase chain reaction (PCR) testing.
Cutaneous SCCs were identified within a cohort of 331
individuals with LS, with a proven germline mutation, from
194 families, derived from two Dutch hospitals (January 2000
to October 2016), as described previously.6 The study was
approved by the institutional review board of the Netherlands
Cancer Institute (IRBm19-123).
Pathology reports and formalin-fixed paraffin-embedded tis-
sues were obtained for histopathological reassessment. IHC
was performed according to standard protocols on slides for
MMR proteins for the Ventana immunostainer (Roche Diag-
nostics Limited, Burgess Hill, UK). The proteins studied were
MLH1 (clone ES05; Agilent, Santa Clara, CA, USA), MSH2
(clone G219-1129; Roche), MSH6 (clone EP49; Epitomics,
Burlingame, CA, USA) and PMS2 (clone A16-4; Roche). Cuta-
neous SCCs with absent staining of one or more MMR pro-
teins were considered MMR deficient.
DNA was isolated using a Qiagen extraction kit (Qiagen,
Venlo, the Netherlands). A pentaplex PCR-based assay for MSI
was performed using fluorescent-labelled primers of five
mononucleotide repeat targets (BAT25, BAT26, NR24, NR21
and NR27), followed by fragment analysis. MSI was defined
as instability in two or more markers.
In 331 individuals with LS, in total 13 cutaneous SCCs were
diagnosed in eight patients (24%) (11 SCCs as described ear-
lier and two additional SCCs identified in 2015 and 2017
within this cohort). Tissue from 10 of these 13 cutaneous
SCCs in seven patients was available for further analyses. Three
patients were diagnosed with two SCCs each. Two patients
were male (29%) and the majority were diagnosed with an
MSH2 germline mutation (86%; Table 1). Five patients had a
history of dermatological neoplasms prior to SCC diagnosis.
The median age at diagnosis of the first cutaneous SCC was
52 years (range 33–60).
MMR IHC and MSI PCR testing were performed in the 10 and
nine available cutaneous SCCs, respectively (from one sample
there was not enough DNA available). MMR deficiency was
detected in all 10 cutaneous SCCs by IHC, with the deficiencies
corresponding to the LS germline mutations. MSI PCR demon-
strated MSI in three of nine cutaneous SCCs, resulting in a discor-
dance of 67% between MMR IHC and MSI PCR. All of these three
patients had two cutaneous SCCs, with both concordant and dis-
cordant results between MMR IHC and MSI PCR (Table 1).
We showed that all cutaneous SCCs diagnosed in individuals
with LS were MMR deficient, with loss of staining of MMR
proteins corresponding to the known germline mutation, sug-
gesting that SCC is an LS-associated tumour. We assume that
MMR-deficient cutaneous SCCs develop by a germline muta-
tion in one of the MMR genes, followed by a second hit of
the wildtype copy.
Concordance between MMR IHC and MSI PCR is high for
colorectal and endometrial cancer, but a low concordance has
been described for other (skin) malignancies.7,8 Explanations
can be that high tumour turnover is necessary to induce
enough detectable MSI or that the standard pentaplex panel is
not effective for all tumours.8 Therefore, we suggest perform-
ing only MMR IHC to detect LS in cutaneous SCC.
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